Autolus Therapeutics plc (AUTL) — SEC Filings

Latest SEC filings for Autolus Therapeutics plc (AUTL), explained in plain English.

Sentiment Overview: 2 bullish, 39 neutral, 2 mixed

Recent Filings (43)

• 8-K Filing — 8-K · 2026-03-27T08:02:10-04:00 [neutral]
• Autolus Therapeutics Announces Leadership Changes — 8-K · 2025-12-02T00:00:00.000Z [neutral] Risk: medium
  Autolus Therapeutics plc announced on December 1, 2025, the departure of Dr. Christian Itin as Chief Medical Officer and the appointment of Dr. Laura Johnson as
• Autolus Narrows Q3 Loss Amid AUCATZYL Launch, Cash Drains — 10-Q · 2025-11-12T00:00:00.000Z [mixed] Risk: high
  Autolus Therapeutics plc reported a net loss of $79.1 million for the three months ended September 30, 2025, a slight improvement from the $82.1 million net los
• Autolus Therapeutics plc Files 8-K — 8-K · 2025-08-12T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• Autolus Therapeutics plc Files 8-K on Shareholder Matters — 8-K · 2025-06-27T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed an 8-K on June 27, 2025, reporting on matters submitted to a vote of security holders as of June 26, 2025. The filing details the
• 8-K Filing — 8-K · 2025-06-02T00:00:00.000Z [neutral]
• Autolus Therapeutics Appoints New Director — 8-K · 2025-05-30T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc announced on May 23, 2025, a change in its board of directors. Dr. Christian Höbat has been appointed as a new director. The company al
• Autolus Therapeutics plc Files S-1 — S-1 · 2025-05-08T00:00:00.000Z [neutral] Risk: medium
  Autolus Therapeutics plc filed an S-1 registration statement on May 8, 2025, for an unspecified offering. The company, incorporated in England and Wales, is bas
• Autolus Therapeutics Q1 2025 10-Q Filed — 10-Q · 2025-05-08T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed its 10-Q for the period ending March 31, 2025. The company, focused on biological products, reported financial data for the first
• Autolus Therapeutics Files 8-K — 8-K · 2025-04-23T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed an 8-K on April 23, 2025, reporting on financial statements and exhibits. The company, incorporated in England and Wales, is invo
• Autolus Therapeutics Reports Board Changes and Financials — 8-K · 2025-04-03T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed an 8-K on February 28, 2025, reporting changes in its board of directors and compensatory arrangements. The filing also includes
• Autolus Therapeutics plc Files 8-K — 8-K · 2025-03-20T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• Autolus Therapeutics Files 8-K — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Autolus Therapeutics Q3 2024 Update — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Autolus Therapeutics plc filed its 10-Q for the period ending September 30, 2024. The company reported operating expenses of £104.7 million for the nine months
• SC 13G Filing — SC 13G · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• PPF Group Amends Autolus Therapeutics Stake Filing — SC 13D/A · 2024-10-25T00:00:00.000Z [neutral] Risk: medium
  PPF Group N.V. and its affiliates, including AMALAR HOLDING S.R.O. and RENATA KELLNEROVA, filed an amendment to their Schedule 13D on October 25, 2024, regardin
• Autolus Therapeutics plc Files 8-K — 8-K · 2024-09-26T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed an 8-K on September 26, 2024, reporting on events that occurred on the same date. The filing pertains to Regulation FD Disclosure
• AstraZeneca to Acquire Autolus Therapeutics for $6B — 8-K · 2024-09-19T00:00:00.000Z [bullish] Risk: medium
  Autolus Therapeutics plc announced on September 13, 2024, that it has entered into a definitive agreement to be acquired by AstraZeneca for approximately $6.0 b
• Autolus Therapeutics Enters Material Definitive Agreement — 8-K · 2024-09-13T00:00:00.000Z [neutral] Risk: medium
  Autolus Therapeutics plc announced on September 10, 2024, that it has entered into a material definitive agreement. The filing does not provide specific details
• Autolus Therapeutics plc Files Q2 2024 10-Q — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  Autolus Therapeutics plc filed its 10-Q for the period ending June 30, 2024. The company reported its financial results for the second quarter and first half of
• Autolus Therapeutics Files 8-K on Shareholder Votes — 8-K · 2024-06-28T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed an 8-K on June 28, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific d
• 8-K Filing — 8-K · 2024-06-05T00:00:00.000Z [neutral]
• Autolus Sells AUTO1/28 for $100M Upfront — 8-K · 2024-06-03T00:00:00.000Z [neutral] Risk: medium
  Autolus Therapeutics plc announced on May 31, 2024, that it has entered into a definitive agreement to sell its AUTO1/28 product candidate and related assets to
• Blackstone Amends Stake in Autolus Therapeutics — SC 13D/A · 2024-05-21T00:00:00.000Z [neutral] Risk: medium
  On May 21, 2024, Blackstone Inc. filed an SC 13D/A amendment regarding Autolus Therapeutics plc. This filing indicates a change in beneficial ownership, with Bl
• Autolus Therapeutics Files Q1 2024 10-Q — 10-Q · 2024-05-17T00:00:00.000Z [neutral] Risk: medium
  Autolus Therapeutics plc filed a 10-Q for the period ending March 31, 2024. The company reported its financial results and operational highlights. Key financial
• Autolus Sells AUTO1/299 to BioNTech for $100M Upfront — 8-K · 2024-05-13T00:00:00.000Z [neutral] Risk: medium
  Autolus Therapeutics plc announced on May 13, 2024, that it has entered into a definitive agreement to sell its AUTO1/299 program to BioNTech SE for an upfront
• Autolus Therapeutics Appoints New CMO, Adds Director — 8-K · 2024-04-01T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc announced on March 26, 2024, the appointment of Dr. Christian Itin as Chief Medical Officer and the election of Ms. Sarah L. Kelly to i
• Kellnerova Amends Autolus Therapeutics Stake Filing — SC 13D/A · 2024-03-25T00:00:00.000Z [neutral] Risk: medium
  Renata Kellnerova, through PPF Biotech B.V. and PPF Group N.V., has amended their Schedule 13D filing for Autolus Therapeutics plc on March 25, 2024. This amend
• Autolus Therapeutics plc Files 2023 10-K — 10-K · 2024-03-21T00:00:00.000Z [neutral] Risk: medium
  Autolus Therapeutics plc filed its 2023 10-K on March 21, 2024, reporting on its operations for the fiscal year ending December 31, 2023. The company, based in
• Autolus Therapeutics plc Files 8-K/A Amendment — 8-K/A · 2024-03-15T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed an 8-K/A on March 15, 2024, to amend a previous filing. The amendment pertains to the 'Results of Operations and Financial Condit
• Autolus Therapeutics Closes $100M ADS Offering — 8-K · 2024-03-14T00:00:00.000Z [bullish] Risk: medium
  On March 14, 2024, Autolus Therapeutics plc announced the closing of its previously announced underwritten public offering of American Depositary Shares (ADSs),
• BioNTech Files SC 13D on Autolus Therapeutics Stake — SC 13D · 2024-02-21T00:00:00.000Z [neutral] Risk: low
  BioNTech SE filed an SC 13D on February 21, 2024, regarding its ownership in Autolus Therapeutics plc. The filing indicates BioNTech SE's continued interest in
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• Autolus Therapeutics Files 8-K for Regulation FD Disclosure — 8-K · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  Autolus Therapeutics plc filed an 8-K on February 13, 2024, to report an event occurring on the same date. The filing, identified by accession number 0001193125
• Autolus Therapeutics Sells Unregistered Equity, Raises Capital — 8-K · 2024-02-08T00:00:00.000Z [mixed] Risk: medium
  Autolus Therapeutics plc entered into a material definitive agreement on February 6, 2024, involving an unregistered sale of equity securities. This indicates t
• Tetragon Financial Amends Autolus Therapeutics Stake — SC 13G/A · 2024-01-31T00:00:00.000Z [neutral]
  Tetragon Financial Management LP, along with its group members Patrick G. G. Dear and Reade E. Griffith, filed an amended SC 13G/A on January 31, 2024, indicati
• Autolus Therapeutics Files Routine 8-K on Jan 26 — 8-K · 2024-01-26T00:00:00.000Z [neutral]
  Autolus Therapeutics plc filed an 8-K on January 26, 2024, reporting an event that occurred on January 22, 2024. This filing is a routine update under Regulatio
• Autolus Therapeutics Reports Officer/Director Changes, Comp. Arrangements — 8-K · 2024-01-10T00:00:00.000Z [neutral]
  Autolus Therapeutics plc filed an 8-K on January 10, 2024, reporting an event that occurred on January 9, 2024, related to the departure or election of director